Lineage Cell Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | $4.3M | $1.8M | $3.5M | $5.0M |
| Cost of Revenue | — | $334.0K | $671.0K | $728.0K | $1.4M | $385.0K | $412.0K | $302.0K |
| Gross Profit | — | $9.2M | $8.3M | $14.0M | $2.9M | $1.4M | $3.1M | $4.7M |
| Gross Margin | — | 96.5% | 92.5% | 95.0% | 67.2% | 78.9% | 88.3% | 93.9% |
| Operating Expenses | ||||||||
| Research & Development | $17.7M | $12.5M | $15.7M | $14.0M | $33.9M | $12.3M | $17.9M | $21.0M |
| SG&A Expense | $18.5M | $18.2M | $17.3M | $22.5M | $18.2M | $15.6M | $24.0M | $24.7M |
| Operating Income | $-36.6M | $-21.5M | $-24.7M | $-22.5M | $-49.2M | $-26.4M | $-38.9M | $-41.8M |
| Operating Margin | -251.6% | -226.1% | -276.5% | -153.2% | -1,133.6% | -1,448.4% | -1,106.0% | -837.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-68.6M | $-18.6M | $-23.3M | $-25.8M | $-43.3M | $-21.9M | $-19.2M | $-47.1M |
| Income Tax Expense | $-5.3M | $0 | $-1.8M | $541.0K | — | $-1.2M | $-7.4M | $346.0K |
| Net Income | $-63.5M | $-18.6M | $-21.5M | $-26.3M | $-43.0M | $-20.6M | $-11.7M | $-46.0M |
| Net Margin | -436.5% | -195.9% | -240.2% | -178.7% | -991.0% | -1,130.8% | -333.1% | -922.0% |
| EPS (Basic) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 | $-0.36 |
| EPS (Diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 | $-0.36 |
| Shares Outstanding (Basic) | 230.1M | 200.2M | 172.7M | 169.8M | 164.5M | 153.1M | 149.8M | 127.1M |
| Shares Outstanding (Diluted) | 230.1M | 200.2M | 172.7M | 169.8M | 164.5M | 153.1M | 149.8M | 127.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |